Price$20.20+0.48 (+2.46%)
01:30 PM07:45 PM
News · 26 weeks74+167%
2026-01-182026-07-12
Mix3590d
- Insider22(63%)
- SEC Filings7(20%)
- Other4(11%)
- Earnings2(6%)
Latest news
25 items- INSIDERDirector Gaynor Richard bought $33,071 worth of American Depositary Shares (1,736 units at $19.05), increasing direct ownership by 2% to 80,737 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERChairperson & CEO Du Ying converted options into 29,048 units of American Depositary Shares and covered exercise/tax liability with 11,431 units of American Depositary Shares, increasing direct ownership by 1% to 1,221,401 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERChairperson & CEO Du Ying sold $130,220 worth of American Depositary Shares (7,026 units at $18.53) and converted options into 17,970 units of American Depositary Shares, increasing direct ownership by 0.92% to 1,203,784 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERChief Legal Officer Edmondson Frazor Titus Iii converted options into 14,600 units of American Depositary Shares and sold $71,642 worth of American Depositary Shares (4,103 units at $17.46), increasing direct ownership by 53% to 30,346 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERChairperson & CEO Du Ying converted options into 58,800 units of American Depositary Shares and sold $428,545 worth of American Depositary Shares (24,543 units at $17.46), increasing direct ownership by 3% to 1,192,840 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERChief Financial Officer Chen Yajing converted options into 6,250 units of American Depositary Shares and sold $39,532 worth of American Depositary Shares (2,264 units at $17.46), increasing direct ownership by 13% to 35,691 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Lis William sold $127,354 worth of American Depositary Shares (7,040 units at $18.09) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 50,437 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Wirth Peter was granted 22,371 units of American Depositary Shares, increasing direct ownership by 6% to 416,121 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Diekman John D was granted 22,371 units of American Depositary Shares, increasing direct ownership by 22% to 122,140 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Morrison Scott W was granted 22,371 units of American Depositary Shares, increasing direct ownership by 65% to 56,904 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Moulder Leon O Jr was granted 22,371 units of American Depositary Shares, increasing direct ownership by 31% to 94,973 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Leung Nisa was granted 22,371 units of American Depositary Shares, increasing direct ownership by 30% to 96,297 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Gaynor Richard was granted 22,371 units of American Depositary Shares, increasing direct ownership by 40% to 79,001 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Vounatsos Michel was granted 22,371 units of American Depositary Shares, increasing direct ownership by 44% to 72,787 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Lis William was granted 22,371 units of American Depositary Shares, increasing direct ownership by 64% to 57,477 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- SECSEC Form 144 filed by Zai Lab Limited144 - Zai Lab Ltd (0001704292) (Subject)
- SECZai Lab Limited filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Zai Lab Ltd (0001704292) (Filer)
- PRZai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas- European Medicines Agency's Committee for Orphan Medicinal Products recognized zoci's preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) - SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options - EMA designation for zoci in pulmonary NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the AACR Annual Meeting in April
- PRZai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China - TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial's China subpopulation Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that China's National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This approval is based
- INSIDERSEC Form 4 filed by Operating Partner Wang Yizhe4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERSEC Form 3 filed by new insider Wang Yizhe3 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERChairperson & CEO Du Ying gifted 107,700 units of American Depositary Shares, decreasing direct ownership by 9% to 1,158,583 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- PRZai Lab Announces Changes to Senior Leadership TeamZai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh Smiley, President and COO, will no longer be with the Company, effective Friday, May 22. "I want to thank Josh for his contributions to Zai Lab over the past three and a half years and wish him well in his future endeavors," said Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab. Zai Lab anticipates multiple clinical data readouts in 2026 for its lead global investigational therapies, including zoci in first-line ES-SCLC and extrapulmonary
- SECZai Lab Limited filed SEC Form 8-K: Leadership Update8-K - Zai Lab Ltd (0001704292) (Filer)
- INSIDERChairperson & CEO Du Ying exercised 261,092 units of American Depositary Shares at a strike of $1.74 and covered exercise/tax liability with 117,435 units of American Depositary Shares, increasing direct ownership by 13% to 1,266,283 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
ZLAB FAQ
7 questionsWhat does Zai Lab Limited do?
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, and infectious diseases primarily in Greater China. The company's commercial products include Zejula for the treatment of breast cancer and non-small cell lung cancer; Optune, a device that delivers tumor treating fields; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer...Where does ZLAB stock trade?
Zai Lab Limited (ZLAB) is listed on NASDAQ.What sector and industry is ZLAB in?
Zai Lab Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Zai Lab Limited go public?
Zai Lab Limited (ZLAB) completed its IPO in 2017.What are analysts saying about ZLAB?
Zai Lab Limited has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy on 2025-08-25. Recent price targets range from $3610.00 to $4750.00.What companies are similar to ZLAB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ZLAB side-by-side with any of them on Quantisnow.How can I track ZLAB on Quantisnow?
Quantisnow aggregates Zai Lab Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZLAB to receive live email and push alerts on every new disclosure.